Pharmacolog AB have received a patent approval from the European Patent Office, EPO, regarding method and technology for adaptive dose regulation in connection with intravenous drug treatments.
In 2018, the US Patent Office approved the Company’s patent application regarding the method and system for dose control of the drug concentration in the infusion liquid during treatment. The company has now obtained the corresponding patent in Europe. The patent applies to dose control based on physiological and biological response parameters such as temperature, respiration, biomarkers in various body fluids. The patent application has now been approved by the European Patent Office and is valid until 2036.
Hans Dahlin, Founder and Head of Research comments: “This is very gratifying that we are now further strengthening the company’s patent situation regarding new products in Personalized Medicine. In order to offer truly individualized care, it is necessary to change the way how medication is administered to patients. Effective treatment of severe conditions requires continuous consideration of the patient’s reactions. Our ongoing research and development project with the academic hospital regarding antibiotics clearly shows these needs. A well thought out and planned patent portfolio in this area will be important to us for future product launches.”
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.